CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025
Watching Cannabis Stocks; Marijuana Moment Reports 'Trump White House Invites Proposal On Federal Marijuana Legalization, Activist Says'
Cannabis Stock Movers For February 17, 2025
CV Sciences Unveils New Aura Collection THC Fizz Tablets
Bearish Sentiment Across The Cannabis Space - Check Full Movers For January 20, 2025
FDA Solicits Public Comments On Use Of Cannabis-derived Products In Veterinary Medicine
Cannabis Stock Gainers And Losers From December 24, 2024
Dropbox Shares Are Trading Higher After the Company Secured a $2 Billion Term Loan Facility Led by Blackstone, Authorized a $1.2 Billion Share Repurchase Program, and Stated It Expects to Meet or Exceed Q4 and FY 2024 Guidance.
Express News | Cv Sciences: On Nov 20, Got Final Arbitration Award From American Arbitration Association Finding Against Michael J. Mona on All Claims for Relief
Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To Know
CV Sciences: Acquisition Is Expected to Create Opportunity to Increase Sales >CVSI
Express News | Cv Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
Press Release: CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
CV SCIENCES INC | 10-Q: Q3 2024 Earnings Report
CV Sciences Q3: Revenue Stable Amid New Launches, Financing
CV SCIENCES INC | 8-K: CV Sciences, Inc. Reports Third Quarter 2024 Financial Results
CV Sciences Non-GAAP EPS of $0.00, Revenue of $3.87M
Express News | Cv Sciences Q3 Operating Expenses USD 2.119 Million
Express News | Cv Sciences Q3 Gross Profit USD 1.778 Million
Press Release: CV Sciences, Inc. Reports Third Quarter 2024 Financial Results